These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 36403884)
1. Small biotechs versus large pharma: Who drives first-in-class innovation in oncology? Kennedy KH; Gomez K; Thovmasian NJ; Chang DC Drug Discov Today; 2023 Feb; 28(2):103456. PubMed ID: 36403884 [TBL] [Abstract][Full Text] [Related]
2. Pharma Success in Product DevelopmentâDoes Biotechnology Change the Paradigm in Product Development and Attrition. Evens RP AAPS J; 2016 Jan; 18(1):281-5. PubMed ID: 26475480 [TBL] [Abstract][Full Text] [Related]
3. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance. Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332 [TBL] [Abstract][Full Text] [Related]
4. The impact of external innovation on new drug approvals: A retrospective analysis. Liu X; Thomas CE; Felder CC Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998 [TBL] [Abstract][Full Text] [Related]
5. Overcoming the obstacles in the pharma/biotech industry: 2008 update. Graul AI; Revel L; Rosa E; Cruces E Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies. Tay-Teo K; Ilbawi A; Hill SR JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967 [TBL] [Abstract][Full Text] [Related]
7. Guidelines, editors, pharma and the biological paradigm shift. Singh AR; Singh SA Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616 [TBL] [Abstract][Full Text] [Related]
8. Partnership between small biotech and big pharma. Wiederrecht GJ; Hill RG; Beer MS IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465 [TBL] [Abstract][Full Text] [Related]
9. The Origin of First-in-Class Drugs: Innovation Versus Clinical Benefit. Osipenko L; Potey P; Perez B; Angelov F; Parvanova I; Ul-Hasan S; Mossialos E Clin Pharmacol Ther; 2024 Feb; 115(2):342-348. PubMed ID: 37983965 [TBL] [Abstract][Full Text] [Related]
10. Biotechs follow big pharma lead back into academia. Kling J Nat Biotechnol; 2011 Jul; 29(7):555-6. PubMed ID: 21747364 [No Abstract] [Full Text] [Related]
11. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models. Chung TD Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951 [TBL] [Abstract][Full Text] [Related]
12. 2016 in review: FDA approvals of new molecular entities. Griesenauer RH; Kinch MS Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460 [TBL] [Abstract][Full Text] [Related]
13. Overcoming the obstacles in the pharma/biotech industry: 2009 update. Graul AI; Revel L; Tell M; Rosa E; Cruces E Drug News Perspect; 2010; 23(1):48-63. PubMed ID: 20155219 [TBL] [Abstract][Full Text] [Related]